Circulating tumour cells to drive the use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer

N Beije,I E de Kruijff,J J de Jong, S O Klaver,P de Vries, R A L Jacobs,D M Somford,E Te Slaa,A G van der Heijden,J Alfred Witjes, L M C L Fossion, E R Boevé, J van der Hoeven,H H E van Melick,C J Wijburg, H Bickerstaffe,J W M Martens,R de Wit,J Kraan, S Sleijfer,J L Boormans

ESMO Open（2022）

引用 8|浏览10

暂无评分

摘要

•Two-year OS in CTC-negative MIBC patients did not meet the criterion for trial success.•CTCs are prognostic for cancer-related mortality and relapse-free survival in MIBC.•CTC-positive MIBC patients survived longer when receiving NAC in explorative analyses.•The absence of CTCs alone is insufficient to withhold NAC in MIBC patients.

查看译文

关键词

circulating tumour cells,neoadjuvant chemotherapy,muscle-invasive bladder cancer,CTCs,liquid biopsy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要